Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking
Authors
Keywords
Pazopanib, Cytochrome P450 (CYP) 3A4, Drug–drug interaction
Journal
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
Volume 41, Issue 4, Pages 465-468
Publisher
Springer Nature
Online
2015-03-03
DOI
10.1007/s13318-015-0252-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2
- (2014) Rui Gu et al. BIOCHEMICAL PHARMACOLOGY
- Fluoxetine- and Norfluoxetine-Mediated Complex Drug–Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4
- (2014) J E Sager et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug–drug interaction with ketoconazole
- (2014) Tao Liu et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells
- (2014) Shivani Sharma et al. Integrative Biology
- Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer
- (2014) Ho-Suap Hahn et al. Journal of Gynecologic Oncology
- MicroRNAs as prognostic markers in ovarian cancer
- (2014) Marta Llauradó et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer
- (2014) Andrey V Khrunin et al. PHARMACOGENOMICS
- Herb–drug interaction prediction based on the high specific inhibition of andrographolide derivatives towards UDP-glucuronosyltransferase (UGT) 2B7
- (2014) Hai-Ying Ma et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors
- (2013) Antoinette R. Tan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase 2 Study of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer
- (2013) Stacey M. Stein et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
- (2013) Emma L. Barber et al. Journal of Gynecologic Oncology
- Bioactivation of herbal constituents: simple alerts in the complex system
- (2011) Zhong-Ze Fang et al. Expert Opinion on Drug Metabolism & Toxicology
- Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile
- (2010) X. Li et al. DRUG METABOLISM AND DISPOSITION
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
- (2010) Kae Hashimoto et al. MOLECULAR CANCER THERAPEUTICS
- Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction
- (2009) Zhong-Ze Fang et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities
- (2009) Xiaohai Li et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Structural Alerts, Reactive Metabolites, and Protein Covalent Binding: How Reliable Are These Attributes as Predictors of Drug Toxicity?
- (2009) Amitâ S. Kalgutkar et al. CHEMISTRY & BIODIVERSITY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started